Ardelyx, Inc. vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| ARDX | JNJ | |
|---|---|---|
| Market Cap | $996.75 million | $624.74 billion |
| Revenue (TTM) | $450.89 million | — |
| Net Income (TTM) | $-55,702,000 | — |
JNJ leads on 1 of 1 size & scale factors.
Valuation
| ARDX | JNJ | |
|---|---|---|
| Price / Book | 6.69 | — |
| Price / Sales | 2.21 | — |
ARDX and JNJ split the valuation factors evenly.
Profitability
| ARDX | JNJ | |
|---|---|---|
| Net Margin | -12.35% | — |
| Return on Equity | -37.38% | — |
ARDX and JNJ split the profitability factors evenly.
Dividend
| ARDX | JNJ | |
|---|---|---|
| Dividend Yield | — | 2.05% |
ARDX and JNJ split the dividend factors evenly.
Risk & Sentiment
| ARDX | JNJ | |
|---|---|---|
| Short Interest | 0.76% | 0.67% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: ARDX overview, ARDX financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.